

Version 1.0.3

Submission
Home > Submission

You can use the options below to view your submission. Where appropriate you can also add to and update your submission and send the details for approval.

Submission Details	
Status	Accepted
Open Date	01/10/2016
Deadline Date	31/10/2016
Date Submitted	24/10/2016
Type	Historic Performance in Initiating
NHS provider	Maldstone and Tunbridge Wells NHS Trust

Showing records 1 to 25 of 27.
Pages: 1 2 Next >

Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Submission Type	Name of Trial	Date of Receipt of Valid Research Application	Date of NHS Permission	First Patient Recruited?	Date of First Patient Recruited	Duration between VRA and NHS Permission	Duration between NHS Permission and First Patient	Duration between VRA and First Patient	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Patient Recruited	Duration between Date Site Selected and First Patient Recruited	Benchmark Met	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Not Col Sta
89613	13/NW/0501	123836	HRA Approval	QUAZAR CC-488-AML-001: A Phase 3, randomized, double-blind, placebo-controlled study to compare efficacy and safety of oral azacitidine plus best supportive care versus best supportive care as maintenance therapy in subjects with acute myeloid Leukemia in			No		114						No	12/01/2016	12/01/2016	25/04/2016	26/04/2016	05/05/2016	Please Sel.
89614	14/EM/0172	142310	NHS Permission	BABY OSCAR- Outcome after Selective early Treatment for Closure of patient Ductus Arteriosus in Pre-term babies.		13/10/2015	No		122						No						Please Sel.
				Bay 94-9343 / 15/743: A randomized, open-label, active-controlled, Phase 2 study of intravenous																	

89615	15/EM/0473	187844	HRA Approval	anetumab ravarsine (BAV 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progression			No				112				No	17/02/2016	10/05/2016	15/07/2016	18/08/2016	30/08/2016	Ple Sel	
89616	15/MM/0457	195511	NHS Permission	DARATUMUMAB: An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to a Proteas			Yes	22/03/2016	8	12	20				Yes							Ple Sel
89617	15/LC/1807	187302	NHS Permission	Checkmate 331 An Open-label, Randomized, Phase 3 study of Nivolumab or chemotherapy in subjects with relapsed small-cell lung cancer after Platinum- Based first line chemotherapy. CA209-331		25/01/2016	23/02/2016	Yes	20/07/2016	29	148	177			No							Ple Sel
89618	14/YH/1056	147421	HRA Approval	AB10004 Study- A Multicenter, Randomised, Open-label, three-parallel groups, phase 2-3 study to evaluate the efficacy and safety of mastitib with dexamethasone, gemcitabine with dexamethasone and the combination of mastitib, gemcitabine and dexamethasone			Yes	19/10/2016				95	117	212	No	21/10/2015	21/03/2016	21/06/2016	20/06/2016	24/06/2016	Ple Sel	
89619	13/EM/0348	122371	NHS Permission	Monoprost compared with Lumigan in POA glaucomatocular hypertension		26/10/2015	30/10/2015	No		4					No							Ple Sel

89620	15/LO/1419	183975	NHS Permission	PEARLS: A randomised, phase 3 trial with anti- PD-2 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy	21/03/2016	21/04/2016	No	31																Ple Sel.	
89621	15/EE/0326	185205	NHS Permission	Seattle Genetics: SGN35-023 A randomised, open label, phase 2 study of riluximab and bendamustine with or without brentuximab vedotin for relapsed or refractory CD30- positive diffuse large B-cell lymphoma	23/03/2016	04/04/2016	No	12																	Ple Sel.
89622	14/SS/1043	142447	NHS Permission	UNIRAD: Randomized, doubled-blind, multicentre phase 111 trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with poor prognosis, ER+ and HER2- primary breast cancer who remain free of disease after receiving	06/03/2016	09/03/2016	No	3																	Ple Sel.
89623	15/EM/0344	183906	NHS Permission	MORAB-009-201 A randomised, double-blind, place-controlled study of the safety and efficacy of amatumumab in combination with pemetrexed and cisplatin in subjects with unresectable malignant pleural mesothelioma	14/03/2016	23/03/2016	Yes	19/07/2016	9	118	127														Ple Sel.
89624	15/LO/0940	179018	NHS	Victoria: GS-US- 312-0118 A phase 3 randomised open-label study evaluating the efficacy and safety of idelalisib in combination with obinutuzumab	13/11/2015	22/12/2015	No	39																	Ple

89630	16/H/0154	202759	HRA Approval	Placebo-controlled, parallel-group, Prospective Study to Evaluate the Safety and Efficacy of Domperidone in 6 month old to 12 year old Pediatric Subjects with Nausea and Vomiting due to																																			
				GO29834 - Harmony: A phase Ib/II study evaluating the safety and efficacy of Orlinuzumab in combination with Polatuzumab vedotin and lenalidomide in patients with relapsed or refractory follicular or diffuse large B-cell lymphoma.																																			
89631	16/LO/0092	194133	NHS Permission	A prospective, multicentre, randomised trial: The effect of catheter valve Vs. standard catheter removal in outpatient settings on the patient discharge timings																																			
89632	16/LO/0075	191435	HRA Approval	HART Hughes Abdominal Repair Trial - Abdominal wall closure techniques to reduce incidence of incisional hernias																																			
89633	12/WA/0374	98726	NHS Permission	A randomised clinical trial to evaluate the effectiveness of a multi-modal intervention in frail people with type 2 diabetes on frailty and quality of life: The MID-Frail Study																																			
89634	13/LO/1096	89630	NHS Permission	FIRST Registry: Follow-up in Rivaroxaban patients in the																																			
89635	14/W/S/1120	161050	NHS Permission																																				

